Roche's Chugai pays Halozyme $25M to access subcutaneous delivery tech

Chugai Pharmaceutical has struck a deal for a subcutaneous drug delivery technology, paying Halozyme Therapeutics $25 million upfront to use its Enhanze enzyme against an undisclosed target.